Century Therapeutics, Inc. cotiza a 1.44 USD y tiene una capitalización bursátil de $260M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.11 | $-0.11 | $-0.25 |
| Estimado | $-0.11 | $-0.12 | $-0.17 | $-0.30 |
| Sorpresa | — | +8.3% | +35.3% | +16.7% |
| Métrica | IPSC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -15.8% | -38.6% | +22.8% |
| Net Margin | -8.8% | -33.6% | +24.8% |
| FCF Margin | -95.9% | -13.9% | -82.1% |
| ROE | -6.0% | -40.4% | +34.4% |
| ROA | -4.3% | -32.0% | +27.7% |
| Current Ratio | 5.97 | 2.84 | +3.13 |
| Debt / Equity | — | 0.28 | — |